Literature DB >> 16179652

Prevalence and treatment of depression in Parkinson's disease.

Connie Veazey1, Sahinde Ozlem Erden Aki, Karon F Cook, Eugene C Lai, Mark E Kunik.   

Abstract

Parkinson's disease (PD) is a progressive neurological condition with debilitating symptoms, and depression is a common comorbid condition of this disease. The authors review existing literature on the prevalence and treatment of depression in PD. Prevalence estimates of depression vary widely, ranging from 7%-76%. This variation is due to inconsistent methodology. Treatment options for depression in PD include medication therapy, electroconvulsive therapy (ECT), and psychotherapy. There are few randomized controlled trials of these treatment options. The authors argue for more systematic and controlled research examining both the prevalence and treatment of depression in PD.

Entities:  

Mesh:

Year:  2005        PMID: 16179652     DOI: 10.1176/jnp.17.3.310

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  35 in total

Review 1.  Chaperone-mediated autophagy: machinery, regulation and biological consequences.

Authors:  Wenming Li; Qian Yang; Zixu Mao
Journal:  Cell Mol Life Sci       Date:  2010-10-26       Impact factor: 9.261

Review 2.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

Review 3.  A systematic review and meta-analysis of cognitive behavioral and psychodynamic therapy for depression in Parkinson's disease patients.

Authors:  Cheng-Long Xie; Xiao-Dan Wang; Jie Chen; Hua-Zhen Lin; Yi-He Chen; Jia-Lin Pan; Wen-Wen Wang
Journal:  Neurol Sci       Date:  2015-02-28       Impact factor: 3.307

4.  Dopaminergic modulation of memory and affective processing in Parkinson depression.

Authors:  Lee X Blonder; John T Slevin; Richard J Kryscio; Catherine A Martin; Anders H Andersen; Charles D Smith; Frederick A Schmitt
Journal:  Psychiatry Res       Date:  2013-07-06       Impact factor: 3.222

Review 5.  Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.

Authors:  Moussa B H Youdim; Tamar Amit; Orit Bar-Am; Orly Weinreb; Mara Yogev-Falach
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 6.  Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.

Authors:  Joshua Kuruvilla; Andrew Octavian Sasmita; Anna Pick Kiong Ling
Journal:  Neurol Sci       Date:  2018-08-03       Impact factor: 3.307

Review 7.  Psychiatric symptoms in Parkinson's disease.

Authors:  Frank Schneider; Astrid Althaus; Volker Backes; Richard Dodel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

8.  Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study.

Authors:  Martin Wolz; Alice Kaminsky; Matthias Löhle; Rainer Koch; Alexander Storch; Heinz Reichmann
Journal:  J Neurol       Date:  2009-03-13       Impact factor: 4.849

9.  Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism.

Authors:  Samantha J Podurgiel; Meredith N Milligan; Samantha E Yohn; Laura J Purcell; Hector M Contreras-Mora; Mercè Correa; John D Salamone
Journal:  Neuropsychopharmacology       Date:  2015-03-11       Impact factor: 7.853

10.  Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's disease.

Authors:  Connie Veazey; Karon F Cook; Melinda Stanley; Eugene C Lai; Mark E Kunik
Journal:  J Clin Psychol Med Settings       Date:  2009-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.